$65M round positions SQZ Biotech for potential IPO, 2021 catalysts

SQZ Biotech is adding at least one experienced crossover investor to what could be its last private financing ahead of catalysts expected late this year and next.

SQZ Biotechnologies Co. raised $65 million in a series D round led by new investor Temasek, bringing its total

Read the full 452 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers